Last reviewed · How we verify
epirubicin - cyclophosphamide / docetaxel + bevacizumab
Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Docetaxel is a taxane that stabilizes microtubules, preventing cell division. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), reducing angiogenesis.
Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Docetaxel is a taxane that stabilizes microtubules, preventing cell division. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), reducing angiogenesis. Used for Metastatic breast cancer, Locally advanced or metastatic breast cancer.
At a glance
| Generic name | epirubicin - cyclophosphamide / docetaxel + bevacizumab |
|---|---|
| Sponsor | GBG Forschungs GmbH |
| Drug class | anthracycline antibiotic, alkylating agent, taxane, monoclonal antibody |
| Target | topoisomerase II, DNA, microtubules, VEGF |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Epirubicin's mechanism of action involves intercalating DNA strands, which inhibits topoisomerase II and induces apoptosis. Cyclophosphamide works by cross-linking DNA, causing cell death. Docetaxel stabilizes microtubules, preventing cell division. Bevacizumab inhibits VEGF, reducing angiogenesis. This combination of drugs targets cancer cells and their blood supply, making it difficult for tumors to grow and spread.
Approved indications
- Metastatic breast cancer
- Locally advanced or metastatic breast cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Mucositis
- Hair loss
Key clinical trials
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (PHASE2)
- A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer (PHASE2)
- Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer (PHASE2)
- BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab (PHASE3)
- Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients (PHASE2)
- Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON) (PHASE2)
- Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer (PHASE2)
- Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: